GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Chimeric Therapeutics CHM.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Chimeric Therapeutics — daily ASX:CHM

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Chimeric Therapeutics on TradingView ↗

About Chimeric Therapeutics

Its shares trade on ASX under the ticker CHM.AX. It has been listed since 18 January 2021. In the fiscal year to 30 June 2025, it reported revenue of A$4.0m and a net loss of A$10.4m. At that date it held total assets of A$21.6m and shareholders' equity of A$2.0m.

Chimeric Therapeutics Ltd. develops Chlorotixin CAR-T technology based cell therapies for the curation of solid tumors. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-01-18. The firm is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase I clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The firm is also focused on the development of four NK and CAR NK assets with plans for Phase I clinical trials in solid tumors and blood cancers.

Figures and description from our data supplier, not checked against the company's own report.

More about Chimeric Therapeutics →

Latest on Chimeric Therapeutics

Our reporting

We have not reported on Chimeric Therapeutics yet.

Next results

26 Feb 2027

Due on 26 Feb 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Chimeric Therapeutics's ticker?

Chimeric Therapeutics trades as CHM.AX on ASX, under ISIN AU0000121576.

What was Chimeric Therapeutics's last closing price?

We have not recorded a close for this listing yet. The chart above carries pricing from TradingView.

When does Chimeric Therapeutics next report results?

Results are expected on 26 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.